CXCL10 and its receptor CXCR3 are expressed in the pancreatic β-cell microenvironment in early T1D (64), so CXCL10/CXCR3 antagonists may potentially postpone T1D development (3). The gene discussed is CXCR3; the disease is type 1 diabetes mellitus.